Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncogene|May 29, 2007
Trastuzumab: triumphs and tribulationsR Nahta, F J Esteva
Current Pharmacogenomics and Personalized Medicine|March 20, 2010
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensR Nahta, S Shabaya, T Ozbay, et al.
Current Medicinal Chemistry|March 28, 2013
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1S S Gayle, R C Castellino, M C Buss, et al.
Current Medicinal Chemistry|November 21, 2013
P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancerS M Donnelly, E Paplomata, B M Peake, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR)Q Dong, S P Johnson, O M Colvin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2007
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancerF Andre, R Nahta, R Conforti, et al.
Pageof 1